Press-release for stocks related to als

Prices are updated after-hours

tags : Als

save search

FDA Grants Accelerated Approval for QALSODY™ (tofersen) for SOD1-ALS, a Major Scientific Advancement as the First Treatment to Target a Genetic Cause of ALS
Published: 2023-04-25 (Crawled : 20:00) - globenewswire.com
IONS | $42.455 1.47% 1.45% 730K

Health Technology

| 18.31% | O: 0.03% H: 0.77% C: -0.39%
BIIB | $201.91 4.52% 4.32% 3.3M

Health Technology

| -28.48% | O: -1.35% H: 3.82% C: 3.39%
fda genetic als approval treatment grants

NeuroSense CEO Provides Q1 2023 Update: Phase 2b ALS Trial Achieves 80% Enrollment
Published: 2023-04-17 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -17.79% | O: -4.29% H: 5.13% C: 2.56%
ceo als trial

Clene Announces the Plenary Presentations of MS and ALS Data Supporting the Efficacy and Safety of CNM-Au8® at the 2023 American Academy of Neurology Annual Meeting
Published: 2023-04-11 (Crawled : 12:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -68.81% | O: 0.92% H: 0.0% C: -1.82%
au8 als meeting

Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
Published: 2023-04-10 (Crawled : 14:00) - biospace.com/
DNLI | $15.55 -3.48% -3.6% 940K

Health Technology

| -35.91% | O: -1.07% H: 0.79% C: 0.21%
dnl343 als meeting therapeutics

NeuroSense Therapeutics & Massachusetts General Hospital's NeuroEpigenetics Lab to Collaborate on Elucidating Neurotherapeutic Effects of PrimeC in ALS
Published: 2023-03-27 (Crawled : 13:20) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -22.99% | O: -2.3% H: 2.35% C: -2.35%
primec als therapeutics

BrainStorm Cell Therapeutics Announces FDA Advisory Committee Meeting to Review Biologics License Application for NurOwn® for the Treatment of ALS
Published: 2023-03-27 (Crawled : 11:00) - biospace.com/
BCLI A | $0.5339 1.7% 1.67% 190K

Health Technology

| -64.52% | O: 16.13% H: 6.67% C: -11.11%
nurown fda als license review cell treatment meeting application therapeutics

NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
Published: 2023-03-23 (Crawled : 13:20) - prnewswire.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -18.79% | O: 0.0% H: 4.85% C: 0.61%
conference disease als alzheimer's therapy

NeuroSense to Present at the ALS and Alzheimer's Disease at AD/PD™ 2023 Advances in Science & Therapy Conference
Published: 2023-03-23 (Crawled : 13:00) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -18.79% | O: 0.0% H: 4.85% C: 0.61%
conference disease als alzheimer's therapy

CNM-Au8® Associated With Delayed Time to Key Clinical Progression Events at Six Months Supporting a Survival Benefit in the Healey ALS Platform Trial
Published: 2023-03-09 (Crawled : 03:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -73.85% | O: 10.0% H: 0.7% C: -5.59%
au8 six als trial platform

Clene's Nanocrystal ALS Treatment Bounces Back with Positive Data
Published: 2023-03-09 (Crawled : 18:00) - biospace.com/
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -73.85% | O: 10.0% H: 0.7% C: -5.59%
treatment als back positive

Clene to Announce New CNM-Au8® Data From the Healey ALS Platform Trial
Published: 2023-03-08 (Crawled : 03:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -73.85% | O: 10.0% H: 0.7% C: -5.59%
au8 als trial platform

New Data Show CNM-Au8® Preserved ALS Patient Function and Slowed Disease Progression in the Open-Label Extension of the Phase 2 RESCUE-ALS Trial
Published: 2023-03-06 (Crawled : 12:00) - globenewswire.com
CLNN 4 | $0.3374 0.69% 0.68% 300K

| -71.67% | O: 6.67% H: 1.56% C: 0.0%
au8 rescue-als disease extension als trial show

Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
Published: 2023-02-27 (Crawled : 14:00) - biospace.com/
COYA | News | $8.28 3.24% 3.14% 120K

| 110.25% | O: 1.25% H: 0.0% C: -4.94%
als association therapeutics study

Seelos Therapeutics Announces Completion of Enrollment of its Phase II/III Trial of SLS-005 in Amyotrophic Lateral Sclerosis on the HEALEY ALS Platform
Published: 2023-02-13 (Crawled : 16:00) - biospace.com/
SEEL | $0.2971 -9.17% -10.1% 600K

Health Technology

| -58.97% | O: 5.32% H: 0.0% C: -7.47%
sls-005 als trial therapeutics sclerosis platform

NeuroSense Receives Approval in Germany to Enroll Patients in its Phase 2b ALS Trial
Published: 2023-02-08 (Crawled : 14:20) - prnewswire.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -12.42% | O: -0.65% H: 23.68% C: 0.0%
enroll als trial approval germany

AC Immune Awarded New Grants from MJFF and Target ALS Supporting Programs Targeting TDP-43
Published: 2023-02-07 (Crawled : 16:00) - biospace.com/
LLY | News | $732.2 -1.81% 0.18% 2.1M

Health Technology

| 122.77% | O: -0.48% H: 1.46% C: 1.08%
ACIU | $2.33 -2.1% -2.15% 320K

Health Technology

| 0.0% | O: 1.27% H: 2.08% C: 0.83%
tdp-43 als grants

NeuroSense Expands its Phase 2b ALS PARADIGM Trial to Canada and Withdraws Protocol from U.S. IND to Align its Clinical Strategy with the FDA for a Potential Pivotal Phase 3 Study
Published: 2023-02-06 (Crawled : 14:20) - neurosense.investorroom.com
NRSN | News | $1.33 -2.21% -2.26% 130K

| -17.79% | O: -4.91% H: 5.81% C: 1.94%
fda canada als trial potential study phase 2b

Amylyx Pharmaceuticals Announces Completion of Enrollment in Global Phase 3 PHOENIX Trial of AMX0035 in ALS
Published: 2023-02-02 (Crawled : 15:00) - biospace.com/
AMLX A | $1.88 -3.59% -3.72% 1.4M

| -95.23% | O: -0.2% H: 3.98% C: -5.88%
amx0035 pharmaceuticals global als trial

CureVac begrüßt Dr. Myriam Mendila als neuen Chief Development Officer
Published: 2023-02-01 (Crawled : 12:00) - curevac.com
GLAXF | News | $19.54 -14.18% 2.6K

Health Technology